KNOLL ANCROD SNAKE VENOM STROKE THERAPY PHASE III TRIALS
Executive Summary
KNOLL ANCROD SNAKE VENOM STROKE THERAPY PHASE III TRIALS are under way at Westchester County Medical Center. New York Medical College (NYMC) neurologists are running the 20-month double-blind, placebo-controlled trial to study the effect of ancrod (European trade name: Arvin), made from the venom of the Malayan pit viper, on ischemic stroke victims. The study is planned to involve approximately 450 subjects at 30 U.S. and Canadian centers, of which 25 have initiated trials thus far. NYMC announced the trial May 9. Phase III trials started in August 1993.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth